Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1626 1772 3791
This examiner grants 75% of resolved cases
Meghan Christine Heasley, an examiner in Tech Center 3700 and Art Unit 1626, has 133 resolved cases. Her allowance rate is 75.2 percent. The median days to allowance is 1126, which provides a clear expectation for the timeline of a successful grant. These metrics offer a consistent look at her examination style across 133 cases. The 1126-day median pendency is a vital data point for managing expectations in Art Unit 1626.
The interview lift for this examiner is 34.0 percent. This is a significant increase, suggesting that interviews are highly effective in her docket. This lift provides a substantial boost to the 75.2 percent base allowance rate. Given the 1126-day median pendency, practitioners should prioritize interviews to navigate the prosecution process more effectively and increase their chances of a grant. The 34.0 percent lift is a major strategic advantage for applicants in Tech Center 3700.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18548356 | (METH)ACRYLATES CONTAINING A 4-THIAZOLIDINONE UNIT AND POLYMERS THEREOF | Non-Final OA | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18548366 | MONOMERS CONTAINING A 4-THIAZOLIDINONE UNIT AND THEIR POLYAMIDE, POLYESTER AND POLYURETHANE POLYCONDENSATES | Non-Final OA | COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN |
| 18578744 | METHODS OF TREATING NEPHROTIC SYNDROME | Final Rejection | The Research Institute at Nationwide Children's Hospital |
| 18566922 | nSMASE2 INHIBITOR PRODRUGS WITH ENHANCED ORAL AND BRAIN EXPOSURES | Non-Final OA | The Johns Hopkins University |
| 18548423 | ANTI-FIBROTIC THERAPIES | Non-Final OA | THE JOHNS HOPKINS UNIVERSITY |
| 17928075 | SMALL MOLECULE INHIBITORS OF GRK5 AND GRK5 SUBFAMILY MEMBERS AND USES THEREOF | Non-Final OA | Purdue Research Foundation |
| 18281732 | FATTY ACID-BIFUNCTIONAL DEGRADER CONJUGATES AND THEIR METHODS OF USE | Non-Final OA | Novartis AG |
| 18684563 | TREATMENT COMPOSITIONS AND METHODS | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18548348 | BENZOXAZOLONE INHIBITORS OF INFLAMMASOMES | Non-Final OA | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS |
| 18539471 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | AstraZeneca AB |
| 18570899 | TRIAZINE INHIBITORS OF CYCLIN-DEPENDENT KINASES | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18593643 | INDOLE COMPOUNDS AND METHODS OF USE | Non-Final OA | GENZYME CORPORATION |
| 18003829 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | Non-Final OA | 4E Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy